Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Small aperture corneal inlay implantation (KAMRA) for presbyopia correction: a retrospective study

Poster Details

First Author: J. Thind INDIA

Co Author(s):                     

Abstract Details


To evaluate the efficacy and safety of monocular implantation of KAMRA in prebyopia correction


Thind Eye Hospital, Jalandhar, India


A retrospective analysis of records of patients who underwent, either monocular pocket emmetropic KAMRA ( PEK) implant alone or combined femtosecond LASIK & KAMRA implant (CLK) , was done regarding demographic data, preoperative and postoperative uncorrected distance visual acuity(UDVA) and corrected distance visual acuity (CDVA) and uncorrected near visual acuity(UNVA) and corrected near visual acuity (CNVA). Any operative and postoperative complications were recorded. The inlay implantation was done in nondominant eye after fashioning a pocket using femtosecond laser.


There were 123 patients (56 males, 67 females) (age range - 45-65 years). The majority of patients were hyperopic presbyopes (64.2%). 92 patients underwent CLK while 31 underwent PEK implant. At last follow up of minimum two years, 91.8% patients were stabilized with UNVA > or = of 20/40 (snellen equivalent). Postoperative, binocular UDVA of 20/20 was achieved in 98.3% of cases. Only 1 patient lost >2 lines of UDVA in eye with implant, which was correctable with spectacles. The implant required recentration in two cases & was explanted in one case, without any sequlae, due to supotimal adaptation.


KAMRA implant is safe, reversible and effective procedure for presbyopia correction. Patient selection and centration of implant is crucial for success of surgery.

Financial Disclosure:


Back to Poster listing